Understanding Minimal Residual Disease (MRD)
Understanding Minimal Residual Disease (MRD): A Guide to Some Helpful Calculations when Analyzing ctDNA Minimal residual disease (MRD)...
At LIQOMICS we strive to improve cancer treatment. Requiring only a blood sample, we use circulating tumor DNA to understand the genetics of an individual cancer and monitor treatment with razor-sharp sensitivity.
LIQOMICS is an academic spin-off company from Cologne, Germany. We aspire to bring our cutting-edge liquid biopsy technology for genotyping and disease monitoring to patients worldwide.
The Liqomics MRD test is a crucial tool for the early detection of low level MRD in cancer patients. With our proprietary workflow and bioinformatics we detect cancer with higher sensitivity than others. This can enable an earlier intervention in case of a relapse and hence an improved disease outcome for the patients.
Sensitivity for Genotyping (SNPs / InDels) > 93%
Specificity for Genotyping (SNPs / InDels) > 99.999%
Sensitivity for MRD detection at MRD level > 10-5 > 88%
Specificity for MRD detection at MRD level > 10-5 > 99%
Limit of Detection for MRD ~ 5 x 10-6
Our proprietary technology allows us to be more sensitive and specific when it comes to genotyping and MRD detection across cancers. This is crucial in situations of low disease burden.
Our assay uses tumor mutations that we identify and track in blood to inform on the genetic drivers of a tumor and to quantify minimal residual disease (MRD)
Here are some publications from our early development showing applications in Hodgkin Lymphoma and CNS Lymphoma.
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood (2024) 143 (6): 522–534.
(LINK: https://doi.org/10.1182/blood.2023022020 )
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection. Med (2021) 2 (10), 1171-1194.
(LINK: https://doi.org/10.1016/j.medj.2021.09.002 )
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. Journal of Clinical Oncology (2024)
(LINK: https://doi.org/10.1200/JCO.23.01867 )
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Understanding Minimal Residual Disease (MRD): A Guide to Some Helpful Calculations when Analyzing ctDNA Minimal residual disease (MRD)...
We are always on the lookout for collaborators. Academic research, start-up or pharmaceutical industry. If you are excited...
Lorem ipsum dolor sit amet, consecte adipiscing elit, sed do eiusmod tempor incidiunt ut labore